CR20200612A - Agonistas del receptor de glp-1 y usos de los mismos - Google Patents
Agonistas del receptor de glp-1 y usos de los mismosInfo
- Publication number
- CR20200612A CR20200612A CR20200612A CR20200612A CR20200612A CR 20200612 A CR20200612 A CR 20200612A CR 20200612 A CR20200612 A CR 20200612A CR 20200612 A CR20200612 A CR 20200612A CR 20200612 A CR20200612 A CR 20200612A
- Authority
- CR
- Costa Rica
- Prior art keywords
- glp
- receptor agonists
- aza
- benzimidazoles
- compounds
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001556 benzimidazoles Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>Se proporcionan en la presente ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza- y 7-aza-bencimidazoles como agonistas de GLP-1R, procesos para elaborar tales compuestos y métodos que comprenden administrar tales compuestos a un mamífero en necesidad de los mismos.</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684696P | 2018-06-13 | 2018-06-13 | |
| US201962846944P | 2019-05-13 | 2019-05-13 | |
| US201962851206P | 2019-05-22 | 2019-05-22 | |
| PCT/IB2019/054867 WO2019239319A1 (en) | 2018-06-13 | 2019-06-11 | Glp-1 receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200612A true CR20200612A (es) | 2021-01-20 |
Family
ID=67003576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200612A CR20200612A (es) | 2018-06-13 | 2019-06-11 | Agonistas del receptor de glp-1 y usos de los mismos |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US10934279B2 (es) |
| EP (2) | EP3806955B9 (es) |
| JP (1) | JP6916968B1 (es) |
| KR (1) | KR102542199B1 (es) |
| CN (1) | CN112533674A (es) |
| AU (1) | AU2019285491B2 (es) |
| BR (1) | BR112020024470A2 (es) |
| CA (1) | CA3045644C (es) |
| CL (1) | CL2020003222A1 (es) |
| CO (1) | CO2020015305A2 (es) |
| CR (1) | CR20200612A (es) |
| CU (1) | CU20200099A7 (es) |
| CY (1) | CY1126097T1 (es) |
| DK (1) | DK3806955T3 (es) |
| EC (1) | ECSP20078651A (es) |
| ES (1) | ES2949954T3 (es) |
| FI (1) | FI3806955T3 (es) |
| GE (1) | GEP20237453B (es) |
| HR (1) | HRP20230631T1 (es) |
| HU (1) | HUE063074T2 (es) |
| IL (1) | IL279300B2 (es) |
| LT (1) | LT3806955T (es) |
| MD (1) | MD3806955T3 (es) |
| MX (1) | MX2020013625A (es) |
| NI (1) | NI202000091A (es) |
| NZ (1) | NZ770240A (es) |
| PE (2) | PE20211601A1 (es) |
| PH (1) | PH12020552069A1 (es) |
| PL (1) | PL3806955T3 (es) |
| PT (1) | PT3806955T (es) |
| RS (1) | RS64323B9 (es) |
| SG (1) | SG11202011465QA (es) |
| SI (1) | SI3806955T1 (es) |
| TW (1) | TWI707683B (es) |
| UA (1) | UA124371C2 (es) |
| UY (1) | UY38261A (es) |
| WO (1) | WO2019239319A1 (es) |
| ZA (1) | ZA202007572B (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| AU2019285570B2 (en) | 2018-06-15 | 2022-03-24 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP2022508203A (ja) * | 2018-11-22 | 2022-01-19 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニスト及びその使用 |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| US20220387402A1 (en) * | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CR20220178A (es) | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| WO2021116874A1 (en) * | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| US20220288030A1 (en) * | 2020-01-29 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| KR20220156535A (ko) | 2020-02-07 | 2022-11-25 | 가셔브룸 바이오, 인크. | 헤테로사이클릭 glp-1 작용제 |
| CN113493447B (zh) * | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202206429A (zh) * | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| US20230234968A1 (en) * | 2020-06-10 | 2023-07-27 | Medshine Discovery Inc. | Methyl-substituted benzobisoxazole compound and use thereof |
| WO2021254470A1 (zh) * | 2020-06-19 | 2021-12-23 | 江苏恒瑞医药股份有限公司 | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| MX2023001311A (es) | 2020-08-06 | 2023-04-18 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
| TW202214622A (zh) * | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| EP4204415A1 (en) | 2020-08-28 | 2023-07-05 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115884969A (zh) * | 2020-09-01 | 2023-03-31 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| CN115515956B (zh) * | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| EP4229050A1 (en) * | 2020-10-13 | 2023-08-23 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114478694A (zh) * | 2020-11-13 | 2022-05-13 | 成都奥达生物科技有限公司 | 一种长效mc4r激动剂 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| JP2024505250A (ja) * | 2021-01-28 | 2024-02-05 | カーモット セラピューティクス インコーポレイテッド | Ｇｐｃｒ受容体アゴニスト、それを含む医薬組成物、及びそれらの使用方法 |
| WO2022184849A1 (en) | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| JPWO2022202864A1 (es) | 2021-03-24 | 2022-09-29 | ||
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| US11858918B2 (en) | 2021-04-21 | 2024-01-02 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| AU2022271223A1 (en) * | 2021-05-03 | 2023-11-02 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| AU2022275931A1 (en) | 2021-05-20 | 2023-11-02 | Eli Lilly And Company | Macrocyclic glucagon-like peptide 1 receptor agonists |
| CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
| CN113480534B (zh) * | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| IL310400A (en) * | 2021-08-04 | 2024-03-01 | Shanghai Hansoh Biomedical Co Ltd | Modulating cycloalkyne derivative preparation method for this, as well as this application |
| EP4393914A1 (en) * | 2021-08-24 | 2024-07-03 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Imidazocyclic compound and application thereof |
| JPWO2023038039A1 (es) | 2021-09-08 | 2023-03-16 | ||
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| KR20240073108A (ko) * | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
| WO2023057414A1 (en) * | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| CN115991685A (zh) | 2021-10-20 | 2023-04-21 | 韶远科技（上海)有限公司 | 一种氧杂环丁烷-2-甲胺的制备方法 |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| WO2023106310A1 (ja) * | 2021-12-07 | 2023-06-15 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト活性を有する芳香族複素環誘導体 |
| CN113974618B (zh) * | 2021-12-12 | 2022-09-13 | 广西澍源智能科技有限公司 | 基于水峰血糖修正的无创血糖测试方法 |
| WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| TW202328114A (zh) * | 2021-12-23 | 2023-07-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Glp-1受體激動劑的可藥用鹽、結晶形式及其製備方法 |
| AU2022422997A1 (en) * | 2021-12-23 | 2024-07-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of glp-1 receptor agonist and preparation method therefor |
| CN116354945A (zh) * | 2021-12-27 | 2023-06-30 | 长春金赛药业有限责任公司 | 一种稠合咪唑羧酸类化合物及其制备方法和应用 |
| WO2023151574A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| WO2023151575A1 (en) * | 2022-02-09 | 2023-08-17 | Gasherbrum Bio Inc. | Heterocyclic glp-1 agonists |
| WO2023152698A1 (en) | 2022-02-10 | 2023-08-17 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| WO2023164358A1 (en) * | 2022-02-28 | 2023-08-31 | Ascletis Bioscience Co., Ltd. | Glp-1r modulating compounds |
| WO2023169436A1 (zh) * | 2022-03-08 | 2023-09-14 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2023228023A1 (en) * | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2024051749A1 (zh) * | 2022-09-06 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 一种glp-1r激动剂化合物的多晶型物及其制备方法与用途 |
| WO2024063143A1 (ja) * | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を有する縮合環化合物 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| USD1011080S1 (en) | 2023-07-28 | 2024-01-16 | Voilasophy, Llc. | Yoga storage rack |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1994021615A1 (en) | 1993-03-18 | 1994-09-29 | Merck Sharp & Dohme Limited | Benzimidazole derivatives |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| EP1235572A2 (en) | 1999-10-29 | 2002-09-04 | MERCK SHARP & DOHME LTD. | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| WO2003060475A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| WO2010114824A1 (en) | 2009-03-30 | 2010-10-07 | Transtech Pharma Inc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| WO2011097491A1 (en) * | 2010-02-04 | 2011-08-11 | Glaxosmithkline Llc | Benzimidazole antiviral agents |
| JP5702855B2 (ja) | 2010-05-13 | 2015-04-15 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤として有用な窒素複素環化合物 |
| ES2602111T3 (es) | 2010-09-30 | 2017-02-17 | Pfizer Inc | Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| CA3001857A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| MX2018007755A (es) | 2015-12-29 | 2018-11-09 | Pfizer | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa. |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| US20220387402A1 (en) * | 2019-05-20 | 2022-12-08 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
-
2019
- 2019-06-10 CA CA3045644A patent/CA3045644C/en active Active
- 2019-06-10 US US16/436,311 patent/US10934279B2/en active Active
- 2019-06-10 TW TW108119890A patent/TWI707683B/zh active
- 2019-06-11 BR BR112020024470-8A patent/BR112020024470A2/pt unknown
- 2019-06-11 PL PL19733151.5T patent/PL3806955T3/pl unknown
- 2019-06-11 UA UAA202007608A patent/UA124371C2/uk unknown
- 2019-06-11 RS RS20230504A patent/RS64323B9/sr unknown
- 2019-06-11 HR HRP20230631TT patent/HRP20230631T1/hr unknown
- 2019-06-11 CN CN201980053632.5A patent/CN112533674A/zh active Pending
- 2019-06-11 SG SG11202011465QA patent/SG11202011465QA/en unknown
- 2019-06-11 LT LTEPPCT/IB2019/054867T patent/LT3806955T/lt unknown
- 2019-06-11 NZ NZ770240A patent/NZ770240A/en unknown
- 2019-06-11 GE GEAP201915517A patent/GEP20237453B/en unknown
- 2019-06-11 FI FIEP19733151.5T patent/FI3806955T3/fi active
- 2019-06-11 EP EP19733151.5A patent/EP3806955B9/en active Active
- 2019-06-11 PT PT197331515T patent/PT3806955T/pt unknown
- 2019-06-11 HU HUE19733151A patent/HUE063074T2/hu unknown
- 2019-06-11 JP JP2020569190A patent/JP6916968B1/ja active Active
- 2019-06-11 PE PE2020001993A patent/PE20211601A1/es unknown
- 2019-06-11 CU CU2020000099A patent/CU20200099A7/es unknown
- 2019-06-11 AU AU2019285491A patent/AU2019285491B2/en active Active
- 2019-06-11 KR KR1020217000940A patent/KR102542199B1/ko active IP Right Grant
- 2019-06-11 EP EP23155747.1A patent/EP4219487A1/en active Pending
- 2019-06-11 PE PE2023003553A patent/PE20240584A1/es unknown
- 2019-06-11 IL IL279300A patent/IL279300B2/en unknown
- 2019-06-11 WO PCT/IB2019/054867 patent/WO2019239319A1/en unknown
- 2019-06-11 SI SI201930570T patent/SI3806955T1/sl unknown
- 2019-06-11 MX MX2020013625A patent/MX2020013625A/es unknown
- 2019-06-11 DK DK19733151.5T patent/DK3806955T3/da active
- 2019-06-11 MD MDE20210363T patent/MD3806955T3/ro unknown
- 2019-06-11 ES ES19733151T patent/ES2949954T3/es active Active
- 2019-06-11 CR CR20200612A patent/CR20200612A/es unknown
- 2019-06-12 UY UY0001038261A patent/UY38261A/es unknown
- 2019-08-08 US US16/535,616 patent/US10676465B2/en active Active
- 2019-08-08 US US16/535,553 patent/US10683281B2/en active Active
-
2020
- 2020-12-01 NI NI202000091A patent/NI202000091A/es unknown
- 2020-12-02 PH PH12020552069A patent/PH12020552069A1/en unknown
- 2020-12-04 EC ECSENADI202078651A patent/ECSP20078651A/es unknown
- 2020-12-04 ZA ZA2020/07572A patent/ZA202007572B/en unknown
- 2020-12-07 CO CONC2020/0015305A patent/CO2020015305A2/es unknown
- 2020-12-11 CL CL2020003222A patent/CL2020003222A1/es unknown
-
2021
- 2021-02-09 US US17/171,385 patent/US20210163455A1/en not_active Abandoned
-
2023
- 2023-07-19 CY CY20231100347T patent/CY1126097T1/el unknown
- 2023-10-09 US US18/483,311 patent/US20240059679A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200612A (es) | Agonistas del receptor de glp-1 y usos de los mismos | |
| ZA202007304B (en) | Glp-1 receptor agonists and uses thereof | |
| PH12019501360A1 (en) | Glp-1 receptor agonists and uses thereof | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| EA201501122A1 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
| CO6660514A2 (es) | Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih | |
| PE20191043A1 (es) | Composicion farmaceutica | |
| CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
| DOP2012000105A (es) | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes | |
| NI201800071A (es) | Compuestos de isoindol | |
| CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
| CO6361921A2 (es) | 3-aminociclopentancarboxamidas | |
| EA202092674A1 (ru) | Агонисты рецептора glp-1 и их применение | |
| CU20160050A7 (es) | Un proceso para preparar isoxaflutol en presencia de un ácido fuerte | |
| CR20140253A (es) | N-(3-{ [ (3- { [ 2 - cloro -5- (metoxi) fenil ] amino } quinoxalin -2- il) amino ] sulfonil } fenil ) -2- metilalaninamida como inhibidor de fosfatidilinositol 3- quinasa para el tratamiento de neoplasias linfoproliferativas | |
| PH12015502657B1 (en) | Interactions of betanodaviruses in infection | |
| MX2020010685A (es) | Uso de derivados del acido tetramico para la reduccion de poblaciones de nematodos. | |
| MA52882B1 (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
| MX2015009560A (es) | Composicion, metodo de obtencion y uso de derivados de selenio organico microencapsulado y/o nanoencapsulado para mamiferos. | |
| UA82244U (ru) | Способ получения вещества с потенциальными физиологическими свойствами -1-(1',1'-дифтор-2'-бром-2'-хлорэтил)-бензимидазол |